AASLD 2012: Final study results show telaprevir is safe and effective for HIV/HCV co-infected people – ELPA – European Liver Patients Association


2012-11-12 14:00

HIV/HCV co-infected people treated with telaprevir (Incivo) triple therapy are significantly more likely to achieve sustained virological response, or a cure, than those treated with pegylated interferon/ribavirin alone, according to final results from Study 110 presented yesterday at The Liver Meeting (the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, or AASLD) in Boston.

Last year’s approval of the first direct-acting hepatitis C drugs ushered in a new treatment paradigm. The hepatitis C virus (HCV) protease inhibitors telaprevir (produced by Janssen/Vertex) and boceprevir (Victrelis, produced by Merck) are licensed in Europe and the US for HCV monoinfected patients, but co-infected people also have a pressing need for better hepatitis C treatment, especially since liver disease tends to progress faster in this population.

Mark Sulkowski from Johns Hopkins University School of Medicine presented final 24-week sustained virological response (SVR24) results from a randomised, controlled phase II trial evaluating triple therapy using telaprevir plus pegylated interferon and ribavirin in previously untreated co-infected patients with difficult-to-treat HCV genotype 1. Earlier SVR12 data were presented at the 2012 Conference on Retroviruses and Opportunistic Infections in March 2012.

The study had two parts. Part A included 13 co-infected participants with CD4 cell counts of at least 500 cells/mm3 who were not yet taking antiretroviral therapy, as recommended by antiretroviral treatment guidelines in effect at the time.

Part B included 47 co-infected people on antiretroviral treatment with stable HIV suppression (HIV RNA